Annual EBITDA
-$330.34 M
+$37.44 M+10.18%
31 December 2023
Summary:
PTC Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$330.34 million, with the most recent change of +$37.44 million (+10.18%) on 31 December 2023. During the last 3 years, it has fallen by -$27.25 million (-8.99%). PTCT annual EBITDA is now -1087.47% below its all-time high of $33.45 million, reached on 31 December 2011.PTCT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$49.90 M
-$14.67 M-41.65%
30 September 2024
Summary:
PTC Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$49.90 million, with the most recent change of -$14.67 million (-41.65%) on 30 September 2024. Over the past year, it has increased by +$26.48 million (+34.67%). PTCT quarterly EBITDA is now -532.64% below its all-time high of $11.53 million, reached on 31 March 2024.PTCT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$105.66 M
+$26.48 M+20.04%
30 September 2024
Summary:
PTC Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$105.66 million, with the most recent change of +$26.48 million (+20.04%) on 30 September 2024. Over the past year, it has increased by +$318.94 million (+75.12%). PTCT TTM EBITDA is now -1830.51% below its all-time high of -$5.47 million, reached on 31 March 2012.PTCT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTCT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.2% | +34.7% | +75.1% |
| 3 y3 years | -9.0% | +47.5% | +64.3% |
| 5 y5 years | -269.2% | -0.7% | +41.7% |
PTCT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -9.0% | +10.3% | -532.6% | +68.2% | at high | +75.1% |
| 5 y | 5 years | -269.2% | +10.3% | -532.6% | +69.9% | at high | +75.1% |
| alltime | all time | -1087.5% | +10.3% | -532.6% | +69.9% | -1830.5% | +75.1% |
PTC Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$49.90 M(+41.6%) | -$105.66 M(-20.0%) |
| June 2024 | - | -$35.23 M(-405.4%) | -$132.14 M(-48.0%) |
| Mar 2024 | - | $11.53 M(-136.0%) | -$253.97 M(-23.1%) |
| Dec 2023 | -$330.34 M(-10.2%) | -$32.07 M(-58.0%) | -$330.34 M(-22.2%) |
| Sept 2023 | - | -$76.38 M(-51.4%) | -$424.60 M(+1.1%) |
| June 2023 | - | -$157.06 M(+142.2%) | -$420.07 M(+16.5%) |
| Mar 2023 | - | -$64.83 M(-48.7%) | -$360.55 M(-2.0%) |
| Dec 2022 | -$367.78 M(-0.1%) | -$126.33 M(+75.8%) | -$367.78 M(+8.6%) |
| Sept 2022 | - | -$71.85 M(-26.3%) | -$338.75 M(-6.4%) |
| June 2022 | - | -$97.54 M(+35.4%) | -$362.00 M(+5.0%) |
| Mar 2022 | - | -$72.06 M(-25.9%) | -$344.80 M(-6.4%) |
| Dec 2021 | -$368.18 M(+21.5%) | -$97.30 M(+2.3%) | -$368.19 M(+24.4%) |
| Sept 2021 | - | -$95.11 M(+18.4%) | -$295.92 M(+37.3%) |
| June 2021 | - | -$80.34 M(-15.8%) | -$215.53 M(-28.4%) |
| Mar 2021 | - | -$95.44 M(+281.4%) | -$300.95 M(-0.7%) |
| Dec 2020 | -$303.09 M(+55.2%) | -$25.03 M(+70.0%) | -$303.09 M(-8.3%) |
| Sept 2020 | - | -$14.72 M(-91.1%) | -$330.36 M(-9.5%) |
| June 2020 | - | -$165.75 M(+69.9%) | -$365.17 M(+58.3%) |
| Mar 2020 | - | -$97.59 M(+86.6%) | -$230.65 M(+18.1%) |
| Dec 2019 | -$195.25 M(+118.2%) | -$52.29 M(+5.6%) | -$195.25 M(+7.8%) |
| Sept 2019 | - | -$49.53 M(+58.6%) | -$181.20 M(+4.8%) |
| June 2019 | - | -$31.24 M(-49.8%) | -$172.82 M(+22.6%) |
| Mar 2019 | - | -$62.19 M(+62.6%) | -$140.94 M(+57.5%) |
| Dec 2018 | -$89.47 M | -$38.24 M(-7.1%) | -$89.47 M(+124.6%) |
| Sept 2018 | - | -$41.16 M(-6461.2%) | -$39.84 M(+106.6%) |
| June 2018 | - | $647.00 K(-106.0%) | -$19.28 M(-39.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$10.72 M(-194.1%) | -$31.59 M(-32.2%) |
| Dec 2017 | -$46.61 M(-63.8%) | $11.39 M(-155.3%) | -$46.61 M(-43.3%) |
| Sept 2017 | - | -$20.60 M(+76.6%) | -$82.18 M(-11.5%) |
| June 2017 | - | -$11.66 M(-54.7%) | -$92.83 M(-20.6%) |
| Mar 2017 | - | -$25.74 M(+6.5%) | -$116.92 M(-9.2%) |
| Dec 2016 | -$128.77 M(-21.6%) | -$24.18 M(-22.6%) | -$128.77 M(-15.3%) |
| Sept 2016 | - | -$31.25 M(-12.6%) | -$151.99 M(-6.3%) |
| June 2016 | - | -$35.74 M(-4.9%) | -$162.21 M(-1.3%) |
| Mar 2016 | - | -$37.59 M(-20.7%) | -$164.41 M(+0.1%) |
| Dec 2015 | -$164.25 M(+69.0%) | -$47.40 M(+14.3%) | -$164.25 M(+10.6%) |
| Sept 2015 | - | -$41.47 M(+9.3%) | -$148.54 M(+10.7%) |
| June 2015 | - | -$37.94 M(+1.3%) | -$134.12 M(+10.9%) |
| Mar 2015 | - | -$37.44 M(+18.1%) | -$120.99 M(+24.5%) |
| Dec 2014 | -$97.18 M(+126.0%) | -$31.69 M(+17.1%) | -$97.18 M(+17.1%) |
| Sept 2014 | - | -$27.06 M(+9.1%) | -$83.00 M(+39.2%) |
| June 2014 | - | -$24.81 M(+82.1%) | -$59.63 M(+22.5%) |
| Mar 2014 | - | -$13.62 M(-22.2%) | -$48.67 M(+13.2%) |
| Dec 2013 | -$43.00 M(+78.4%) | -$17.51 M(+374.9%) | -$43.00 M(+39.3%) |
| Sept 2013 | - | -$3.69 M(-73.4%) | -$30.87 M(-8.0%) |
| June 2013 | - | -$13.86 M(+74.3%) | -$33.57 M(+35.5%) |
| Mar 2013 | - | -$7.95 M(+47.8%) | -$24.77 M(+11.1%) |
| Dec 2012 | -$24.10 M(-172.1%) | -$5.38 M(-15.8%) | -$22.29 M(+31.8%) |
| Sept 2012 | - | -$6.39 M(+26.5%) | -$16.91 M(+60.7%) |
| June 2012 | - | -$5.05 M(-7.7%) | -$10.52 M(+92.3%) |
| Mar 2012 | - | -$5.47 M | -$5.47 M |
| Dec 2011 | $33.45 M | - | - |
FAQ
- What is PTC Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for PTC Therapeutics?
- What is PTC Therapeutics annual EBITDA year-on-year change?
- What is PTC Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for PTC Therapeutics?
- What is PTC Therapeutics quarterly EBITDA year-on-year change?
- What is PTC Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for PTC Therapeutics?
- What is PTC Therapeutics TTM EBITDA year-on-year change?
What is PTC Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PTCT is -$330.34 M
What is the all time high annual EBITDA for PTC Therapeutics?
PTC Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $33.45 M
What is PTC Therapeutics annual EBITDA year-on-year change?
Over the past year, PTCT annual earnings before interest, taxes, depreciation & amortization has changed by +$37.44 M (+10.18%)
What is PTC Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PTCT is -$49.90 M
What is the all time high quarterly EBITDA for PTC Therapeutics?
PTC Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $11.53 M
What is PTC Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PTCT quarterly earnings before interest, taxes, depreciation & amortization has changed by +$26.48 M (+34.67%)
What is PTC Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PTCT is -$105.66 M
What is the all time high TTM EBITDA for PTC Therapeutics?
PTC Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.47 M
What is PTC Therapeutics TTM EBITDA year-on-year change?
Over the past year, PTCT TTM earnings before interest, taxes, depreciation & amortization has changed by +$318.94 M (+75.12%)